Immobilizing A Moving Target: CAR T Cells Hit CD22

Sonia Guedan; Julio Delgado

doi:10.1158/1078-0432.CCR-19-1649

Immobilizing A Moving Target: CAR T Cells Hit CD22

Clin Cancer Res. 2019 Sep 1;25(17):5188-5190. doi: 10.1158/1078-0432.CCR-19-1649. Epub 2019 Jul 2.

Authors

Sonia Guedan¹, Julio Delgado²

Affiliations

¹ Department of Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. sguedan@clinic.cat.
² Department of Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

PMID: 31266831
DOI: 10.1158/1078-0432.CCR-19-1649

Abstract

A key mechanism of resistance to chimeric antigen receptor-modified T cells (CAR-T) is loss or downregulation of target antigens. Low antigen expression on cancer cells prevents full CAR-T-cell activation and persistence. Pharmacologic modulation of target antigen expression offers a novel therapeutic strategy to drive more potent and durable responses.See related article by Ramakrishna et al., p. 5329.

Publication types

Comment

MeSH terms

Cell Line, Tumor
Immunotherapy, Adoptive*
Lymphocyte Activation
Receptors, Antigen, T-Cell*
T-Lymphocytes / immunology

Substances

Receptors, Antigen, T-Cell